Patents by Inventor Xiaoni LIU

Xiaoni LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28
    Patent number: 11912769
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: February 27, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING A DOMAIN ANTIBODY DIRECTED AGAINST CD28
    Publication number: 20220144951
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28
    Patent number: 11267888
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 8, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING A DOMAIN ANTIBODY DIRECTED AGAINST CD28
    Publication number: 20200247890
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Application
    Filed: April 8, 2020
    Publication date: August 6, 2020
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • Method of using antibody polypeptides that antagonize CD40 to treat IBD
    Patent number: 10435475
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 8, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
  • Pharmaceutical Formulation Comprising GLP-1 Analogue and Preparation Method Thereof
    Publication number: 20190060410
    Abstract: The present invention discloses a pharmaceutical composition comprising GLP-1 analogs. In one embodiment, the composition further comprises buffers, stabilizers, isotonic agents, preservatives, or a mixture thereof. The present invention has the advantage of providing a highly stabilized pharmaceutical formulation of a GLP-1 analog suitable for long-term shelf-life and distribution in the commercial pharmaceutical supply chain. The disclosed formulations effectively protect the active ingredient GLP-1 analogs from degradation, oxidation, precipitation, crystallization, and other factors leading to loss of clinical efficacy.
    Type: Application
    Filed: May 12, 2016
    Publication date: February 28, 2019
    Inventors: Xiaoni Liu, Hanxing Li, Chaoliang CHEN, Guochang Ma, Feihu Xu, Tongying Wang, Handong Sun
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING A DOMAIN ANTIBODY DIRECTED AGAINST CD28
    Publication number: 20170240636
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Application
    Filed: September 30, 2015
    Publication date: August 24, 2017
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzamme J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • METHOD OF USING ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40 TO TREAT IBD
    Publication number: 20160355596
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Application
    Filed: March 9, 2015
    Publication date: December 8, 2016
    Inventors: Marek HONCZARENKO, Shah VAISHALI, Xiaoni LIU, Wendy L. TRIGONA, Rong SHI, Suzanne J. SUCHARD, Karen D. PRICE, Linda M. GUSTAVSON